Venlo,
The event, which starts at 12:00
A live webcast is available at https://capitalmarketsday2024.qiagen.com/home/default.aspx. A replay and related materials will be available at this link after the event.
QIAGEN’s leadership team will present the new 2028 targets, highlighting QIAGEN’s vision and strategy to sharpen its focus on growth pillars in the portfolio combined with commitments to solid profitable growth and disciplined capital allocation. This includes plans to return at least
“QIAGEN is moving ahead with a reinvigorated leadership team committed to stepping up with more focus and delivering on our new targets. We are sharpening our focus on our growth pillars, and this reflects our unwavering determination to build and maintain profitable leadership positions in fast-growing markets. We are creating ecosystems around these important pillars as we announce important new product launches to maximize their value to customers across the continuum from research to clinical healthcare. This is combined with QIAGEN raising the bar on profitability and a commitment to create greater value for our shareholders and stakeholders,”
“QIAGEN has developed a strong foundation for continued financial success in delivering solid profitable growth in recent years. We have announced new efficiency initiatives and want to harness the power of digitization to free up resources to enhance growth and profitability. Given our healthy balance sheet and cash flow generation, we are announcing a commitment for significant returns to shareholders while maintaining a high level of investments into our business and seeking value-creating M&A opportunities that strengthen our portfolio and create greater value,”
The 2028 strategy involves the following:
- Sharpen focus on growth pillars to sustain profitable growth
QIAGEN has set a goal for at least
QIAcuity digital PCR: QIAGEN is more than tripling the number of sales specialists supporting QIAcuity to drive adoption as over 100 new assays are launched. The QIAcuity-Dx version is also planned to receive
QIAstat-Dx: QIAGEN confirmed plans for the
QIAGEN Digital Insights: QIAGEN confirmed plans to accelerate investments into this business with at least nine new product launches planned by 2028. These plans also include a 40% expansion in the commercial team to extend the global presence into new geographic markets. QIAGEN intends to continue investing about 20% of QDI sales into R&D to combine the power of AI (artificial intelligence) and human-curated knowledge bases, with plans to grow from the current 5 AI-enabled applications across the portfolio to at least 14 by 2028.
Sample technologies: Two important new instrument launches are planned along with several new consumables kits to strengthen QIAGEN’s leadership in this important first step of lab workflows. QIAsymphony Connect is planned for launch in 2025 as an upgrade of the flagship QIAsymphony automation system, building on over 3,300 cumulative placements. QIAGEN also plans to enter the high-throughput automation market with the launch of QIAsprint Connect in 2026. New kits are planned for use on QIAGEN’s full portfolio of instruments in high-growth applications including liquid biopsy, microbiomes and pathogen detection.
QuantiFERON: QIAGEN is a key enabler of the global initiative to eradicate tuberculosis, a potentially fatal bacterial infection, through its QuantiFERON-TB Gold Plus test. About 60% of the global market for annual latent TB testing remains available for conversion from the tuberculin skin test, as QIAGEN steps up commercialization initiatives backed by its best-in-class test and top automation solution with partners DiaSorin, Tecan and
- Drive efficiency and digitization to fuel growth and improve profitability
QIAGEN announced plans to achieve at least a 31% CER adjusted operating income margin in 2028. Key drivers involve a series of new initiatives to free up resources for reallocation and to expand operational margins.
These initiatives include streamlining the portfolio, in particular the recent decision to discontinue the NeuMoDx system. They also include initiatives to simplify the organization, improve end-to-end processes, in particular through an upgrade of QIAGEN’s SAP enterprise resource system; and optimize the site network. QIAGEN is seeking to harness the power of digitization to fuel growth and improve profitability, with about 30 AI initiatives under way.
- Ensure disciplined capital allocation for growth and shareholder value
QIAGEN plans to continue implementing its disciplined capital allocation strategy anchored by strong cash flow trends and a healthy balance sheet.
This strategy involves (1) profitable organic investments into the business; (2) focused M&A through value-creating transactions, and (3) a new plan to return at least
- Deliver strategy through responsibility, empowerment and reinvigorated leadership
Achieving these 2028 targets can only be done by creating an even stronger culture among QIAGEN’s 6,000 employees in terms of empowerment, accountability and ownership. QIAGEN reaffirmed its commitment to its ESG (Environment, Social, Governance) goals, including a validated target to reach net zero carbon emissions by 2050 and maximize contributions to more than 50 public health partnerships around the world.
About QIAGEN
Forward-Looking Statement
Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the
Source:
Category: Financial
![](https://ml.globenewswire.com/media/M2FkODI0ZDAtNjk2My00NDYzLWEwNGItZjczMzcwMjM0NDcxLTEwMzA5NDM=/tiny/QIAGEN-N-V-.png)
Source:John Gilardi QIAGEN N.V. +49 2103 29 11711 ir@qiagen.comDomenica Martorana QIAGEN N.V. +49 2103 11244 ir@qiagen.comThomas Theuringer QIAGEN N.V. +49 2103 29 11826 pr@qiagen.com Lisa MannagotteraQIAGEN N.V. +49 2103 29 14181 pr@qiagen.com
2024 GlobeNewswire, Inc., source